How can flu season, BCAM and volunteers boost fall trial enrollment?
By Robert Maxwell

Fall is a recruitment inflection point: flu season increases clinic traffic, Breast Cancer Awareness Month (BCAM) amplifies community outreach, and demand for healthy volunteers competes with protocol timelines. For sponsors and sites this seasonality can be an asset if study teams deploy targeted tactics and data-driven timing.
Seasonal dynamics and enrollment levers
Flu season both hurts and helps enrollment. Increased respiratory testing and clinic visits create more touchpoints to screen potential participants, but sites must manage competing priorities, vaccination schedules, and infection-control requirements. Strategies to boost fall enrollment during flu season include aligning study visit windows with local vaccination campaigns, offering flexible remote assessments, and leveraging flu-related clinic traffic for prescreening. Modern clinical trial platforms help streamline the search process for both patients and researchers, turning routine visits into recruitment opportunities without overburdening staff.- Coordinate recruitment with influenza vaccination clinics and occupational health schedules
- Use teleconsent and remote monitoring to reduce in-person burden during peak infection periods
- Deploy targeted digital ads emphasizing convenience and safety during flu season
Industry insider perspective
A protocol operations lead at a mid-size CRO noted: "In 2024–2025 we saw sites that integrated flu-clinic screening and remote baseline visits close enrollment 20% faster across mixed therapeutic areas." This came from operational datasets across community and academic sites.
BCAM, oncology outreach, and patients with treatment-resistant conditions
How breast cancer awareness month affects trial recruitment is nuanced: BCAM drives attention and screening but also heightens demand for trials addressing advanced and treatment-resistant disease stages. 2024-2025 clinical trial data show oncology sites that paired BCAM outreach with dedicated navigation for patients with treatment-resistant conditions experienced higher referral quality, if not always higher volume. The key is converting BCAM visibility into sustained engagement—education, rapid referral pathways, and trial discovery tools that connect survivors and those with limited options to studies that match their biomarker and treatment history.- Time investigator meetings and patient education events around BCAM to capture heightened attention
- Prioritize trials for patients with treatment-resistant conditions with clear inclusion guidance and quicker screening
Impact of healthy volunteer demand and regional sponsorship trends
The impact of healthy volunteer demand on study design is real: fall brings more volunteers (students, seasonal workers) but also competing public health messaging. Sponsors must balance compensation, visit burden, and recruitment windows. Meanwhile, regional university sponsorship trends in emerging therapies are shifting enrollment geography—2024–2025 registries indicate growth in midwestern and southeastern academic hubs sponsoring early-phase biologics, which changes where and how healthy volunteer pools are accessed.- Design shorter, modular visits for healthy volunteers during peak recruiting months
- Leverage university partnerships in regions showing increased sponsorship to diversify enrollment
Patient rights and responsibilities
- Right: Receive clear information about risks, benefits, and alternatives before consenting
- Right: Withdraw from a trial at any time without penalty to standard care
- Responsibility: Provide accurate medical history and follow protocol instructions to the best of their ability
- Responsibility: Report side effects promptly and attend scheduled follow-ups or communicate barriers
Related Articles
x-
x-
x-